CSL CSL.AX
CSL Limited is an Australian biopharmaceutical company that develops and commercializes therapies for rare diseases, vaccines, and plasma-derived products, with a business model based on research and global production. CSL shows solid financial health (score 7.27) with an operating margin of 21.49% and ROIC of 13.21%, although negative ROE (-15.83%) and weak momentum (-16.00%) weigh on its profile. The expanded ANDEMBRY reimbursement in Canada is a positive catalyst, while US regulatory pressure is a risk to watch.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
CSL Limited is an Australian biopharmaceutical company that develops and commercializes therapies for rare diseases, vaccines, and plasma-derived products, with a business model based on research and global production. CSL shows solid financial health (score 7.27) with an operating margin of 21.49% and ROIC of 13.21%, although negative ROE (-15.83%) and weak momentum (-16.00%) weigh on its profile. The expanded ANDEMBRY reimbursement in Canada is a positive catalyst, while US regulatory pressure is a risk to watch.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.3 |
| Quality / Moat | 5.1 |
| Valuation | 5.0 |
| Growth | 5.8 |
| Dividend | 7.0 |
| Momentum | 0.9 |
| Risk & Context | 8.9 |
OVERALL SCORE: 5.8/10
Context and risks
Regulatory pressure on US pharmaceutical pricing (MFN, Medicaid) is a sector risk affecting CSL due to its exposure to the US market, although its rare disease therapy portfolio is partially protected.
News considered in the analysis
- Why Is CSL (ASX:CSL) Launching Its New Flu Vaccine First In The UK? — Lanzamiento estratégico de vacuna en un mercado clave, refuerza la cartera de productos pero sin magnitud material sobre beneficios a corto plazo.
- Expanded ANDEMBRY Reimbursement In Canada Could Be A Game Changer For CSL (ASX:CSL) — Ampliación de reembolso de un fármaco clave en Canadá: amplía el mercado accesible y puede impulsar ingresos de forma material.
- CSL Ltd's Dividend Analysis — Análisis genérico de dividendo sin información nueva.
- Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers — Presión regulatoria sobre precios de medicamentos en EE.UU. podría afectar a CSL, aunque su exposición a Medicaid es limitada.
- Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms — Acuerdos de precios de Medicaid podrían comprimir márgenes en el mercado estadounidense, aunque CSL no está entre las nueve firmas.
Verdict: Hold; fundamentals are solid but valuation is not attractive and momentum is negative. Wait for an improvement in growth dynamics or a pullback in price before considering entry.
Main risk: Regulatory pressure on US drug pricing, which could compress margins in a key market despite the partial protection of its rare disease portfolio.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →